Pharmacokinetics of Infliximab in Children with Moderate-to-Severe Ulcerative Colitis
Authors:
- Zhenhua XuZXZhenhua Xu
- Lakshmi PadgettLPLakshmi Padgett
- Marion BlankMBMarion Blank
- Jewel JohannsJJJewel Johanns
- Anne GriffithsAGAnne Griffiths
- Joyce FordJFJoyce Ford
- Honghui ZhouHZHonghui Zhou
- Cynthia GuzzoCGCynthia Guzzo
- Hugh M. DavisHDHugh M. Davis
- Jeffrey HyamsJHJeffrey Hyams
- 1 December 2013
- journal article
- research article
- Published by Oxford University Press (OUP) in Inflammatory Bowel Diseases
- Vol. 19 (13) , 2753-2762
Abstract
To assess infliximab pharmacokinetics in pediatric ulcerative colitis (UC). This phase 3, randomized, open-label multicenter study enrolled 60 children (6-17 yr) with moderate-to-severely active UC (Mayo score, 6-12; endoscopic subscore, ≥2), despite conventional therapy. Patients received infliximab 5-mg/kg induction infusions at weeks 0, 2, and 6. Week 8 clinical responders (n = 45) were randomized to infliximab 5 mg/kg given every 8 weeks (q8w) through week 46 or every 12 weeks (q12w) through week 42. Patients losing response during maintenance infliximab were eligible to increase the dose (5→10 mg/kg) and/or shorten the dosing interval (q12w→q8w). Blood samples were collected for infliximab concentration and pharmacokinetic determinations. Infliximab pharmacokinetics were not influenced by age (6-11 yr versus 12-17 yr), baseline immunomodulator use, or the extent of UC. At week 8, higher serum infliximab concentrations (≥41.1 μg/mL) were associated with greater proportions of patients achieving efficacy endpoints (clinical response, 92.9%; mucosal healing, 92.9%; and clinical remission, 64.3%) versus those with lower serum concentrations (<18.1 μg/mL; 53.9%, 53.9%, and 30.8%, respectively). At week 30, higher median trough serum infliximab concentrations were observed with infliximab 5 mg/kg q8w (1.9 μg/mL) versus q12w (0.8 μg/mL) and with infliximab 10 mg/kg (2.9 μg/mL) versus 5 mg/kg (1.1 μg/mL) among patients who are regimen adjusted. Infliximab pharmacokinetics/exposure-response relationship in patients with UC aged 6 to 17 years were generally comparable with those observed in reference adult UC populations, supporting using infliximab 5 mg/kg at weeks 0, 2, and 6 followed by maintenance dosing with 5 mg/kg q8w in these patients. A positive relationship was noted between serum infliximab level and clinical effect following induction therapy similar to adults.Keywords
This publication has 14 references indexed in Scilit:
- Extrapolation of Adult Data and Other Data in Pediatric Drug-Development ProgramsPediatrics, 2011
- Pharmacokinetic Properties of Infliximab in Children and Adults with Crohn's Disease: A Retrospective Analysis of Data from 2 Phase III Clinical TrialsClinical Therapeutics, 2011
- Pediatric Inflammatory Bowel Disease: Highlighting Pediatric Differences in IBDGastroenterology Clinics of North America, 2009
- CD14+ intestinal macrophages contribute to the pathogenesis of Crohnʼs disease via IL-23/IFN-gamma axis.Inflammatory Bowel Diseases, 2008
- Development, Validation, and Evaluation of a Pediatric Ulcerative Colitis Activity Index: A Prospective Multicenter StudyGastroenterology, 2007
- Induction and Maintenance Infliximab Therapy for the Treatment of Moderate-to-Severe Crohn’s Disease in ChildrenGastroenterology, 2007
- Infliximab for Induction and Maintenance Therapy for Ulcerative ColitisNew England Journal of Medicine, 2005
- Ethical concerns regarding guidelines for the conduct of clinical research on childrenJournal of Medical Ethics, 2005
- Research with childrenBMJ, 2001
- Coated Oral 5-Aminosalicylic Acid Therapy for Mildly to Moderately Active Ulcerative ColitisNew England Journal of Medicine, 1987